Amcor is a packaging company. Co. has the following reportable segments: Amcor Rigid Plastics, which manufactures rigid plastic containers for a range of primarily beverage and food products; Amcor Flexibles, which represents the aggregation of four operating segments of which each manufactures flexible and film packaging for their respective industries; as well as Other/Investments, which holds Co.'s equity accounted investments in the associate AMVIG Holdings Limited (AMVIG) and the joint venture Discma AG (Discma). AMVIG is mainly involved in the manufacture of tobacco packaging while Discma's operations primarily relate to the development and licensing of packaging product development.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies. The company has four clinical-stage product candidates: AB928, which is an orally bioavailable, reversible antagonist of the adenosine 2a and adenosine 2b receptors; AB680, which is a reversible and selective inhibitor of the CD73 enzyme; AB122, which is a human antibody with similar binding affinity and other characteristics to the marketed anti-PD-1 antibodies pembrolizumab and nivolumab; and AB154, which is a humanized antibody that inhibits an immune checkpoint target involved in a pathway that plays both inhibitory and stimulatory roles in the immune system.

Wynn Resorts is a holding company. Through its subsidiaries, the company is a designer, developer, and operator of resorts featuring hotel rooms, retail space, an array of dining and entertainment options, meeting and convention facilities, and gaming. Through its subsidiary, Wynn Macau, Limited, the company operates two integrated resorts in the Macau Special Administrative Region of the People's Republic of China, Wynn Palace and Wynn Macau. In Las Vegas, NV, the company also operates and, with the exception of certain retail space, own Wynn Las Vegas and Encore Boston Harbor, an integrated resort in Everett, MA, adjacent to Boston.